Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1628173 | 0.88 | — | — | |
| Bromide SCHEMBL4938367 | 0.86 | FDPS (0.41) | FDPSSLC6A3CHRM2CHRM1CHRM3 | |
| SCHEMBL6997367 | 0.85 | FDPS (0.38) | FDPSSLC6A3CHRM2CHRM1CHRM3 | |
| SCHEMBL5846600 | 0.81 | FDPS (0.36) | FDPSSLC6A3CHRM2CHRM1CHRM3 | |
| SCHEMBL2000599 | 0.80 | DRD4 (0.38) | FDPSSLC6A3CHRM2CHRM1CHRM3 | |
| SCHEMBL1051788 | 0.78 | — | — | |
| SCHEMBL5544438 | 0.77 | FDPS (0.37) | FDPSSLC6A3CHRM2CHRM1CHRM3 | |
| SCHEMBL22519197 | 0.76 | MEN1 (0.38) | FDPSCYP2C19ALDH1A1TSHRCYP2D6 | |
| SCHEMBL8671012 | 0.76 | FDPS (0.47) | FDPSSLC6A3CHRM2CHRM1CHRM3 | |
| SCHEMBL2089907 | 0.76 | FDPS (0.42) | FDPSSLC6A3CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712948-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | Renagade Therapeutics Management Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| WO-2024238828-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-4452928-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240067598-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067598-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067598-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2023122752-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | FDPS 984/4885SLC6A3 4289/4885CHRM2 4870/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | FDPS 984/4885SLC6A3 4289/4885CHRM2 4870/4885 |
| US-20240067598-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | FDPS 984/4885SLC6A3 4289/4885CHRM2 4870/4885 |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | FDPS 656/4885SLC6A3 1247/4885CHRM2 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.